Fotios Loupakis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2227424/publications.pdf

Version: 2024-02-01

352 papers	16,972 citations	20797 60 h-index	17580 121 g-index
361 all docs	361 docs citations	361 times ranked	19752 citing authors

#	Article	IF	Citations
1	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 939-944.	1.4	3
2	Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. BMC Gastroenterology, 2022, 22, 17.	0.8	4
3	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103646.	2.0	3
4	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. European Journal of Cancer, 2022, 166, 165-175.	1.3	17
5	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2022, 172, 22-30.	1.3	3
6	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. Tumori, 2021, 107, 46-54.	0.6	2
7	Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients. Critical Reviews in Oncology/Hematology, 2021, 167, 103271.	2.0	1
8	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	0.8	254
9	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	0.9	3
10	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. European Journal of Cancer, 2021, 146, 145-154.	1.3	8
11	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1
12	NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Modern Pathology, 2021, 34, 1547-1557.	2.9	24
13	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.	1.3	29
14	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318.	1.4	7
15	Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1897-1904.	1.2	7
16	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	1.7	7
17	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234
18	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	1.6	3

#	Article	IF	Citations
19	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1
20	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precision Oncology, 2021, 5, 1166-1177.	1.5	55
21	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers, 2021, 13, 5128.	1.7	6
22	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. Journal of Personalized Medicine, 2021, 11, 1095.	1.1	42
23	PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 151-156.	1.4	24
24	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2947.	1.7	4
25	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 2020, 15, e0239439.	1.1	5
26	Practical considerations in the use of regorafenib in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095686.	1.4	16
27	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
28	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. Cancers, 2020, 12, 2049.	1.7	11
29	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells, 2020, 9, 2019.	1.8	30
30	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist, 2020, 25, 803-809.	1.9	26
31	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	2.9	93
32	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. Gastric Cancer, 2020, 23, 1064-1074.	2.7	5
33	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
34	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	1.6	5
35	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clinical Colorectal Cancer, 2020, 19, 219-225.	1.0	45
36	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196

#	Article	IF	Citations
37	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologistsâ€™ perspective. ESMO Open, 2020, 5, e000759.	2.0	161
38	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
39	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	1.9	77
40	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	1.8	63
41	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	1.3	9
42	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. International Journal of Cancer, 2020, 147, 2303-2315.	2.3	14
43	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clinical Colorectal Cancer, 2020, 19, 191-199.e6.	1.0	20
44	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. European Journal of Cancer, 2020, 133, 66-73.	1.3	19
45	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4001-4001.	0.8	35
46	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
47	Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell International, 2019, 19, 209.	1.8	116
48	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patientsâ€™ Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.4	8
49	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€˜BRAF BeCoolâ€™ study. European Journal of Cancer, 2019, 118, 121-130.	1.3	51
50	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine, 2019, 45, 139-154.	2.7	36
51	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	1.3	22
52	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. Annals of Oncology, 2019, 30, v226.	0.6	0
53	Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. Annals of Oncology, 2019, 30, v763-v764.	0.6	0
54	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24

#	Article	IF	Citations
55	PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers, 2019, 11, 1765.	1.7	54
56	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. British Journal of Cancer, 2019, 121, 593-599.	2.9	24
57	Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology, 2019, 37, 3099-3110.	0.8	65
58	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 2019, 18, 245-256.e5.	1.0	2
59	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
60	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. Pharmacogenomics Journal, 2019, 19, 455-464.	0.9	5
61	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
62	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. Expert Review of Respiratory Medicine, 2019, 13, 635-644.	1.0	7
63	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
64	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 2019, 121, 257-263.	2.9	53
65	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	1.3	4
66	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A metaâ€anal ysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	2.3	4
67	Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67
68	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
69	Ramucirumab: the long and winding road toward being an option for mCRC treatment. Expert Opinion on Biological Therapy, 2019, 19, 399-409.	1.4	6
70	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochemical Pharmacology, 2019, 164, 94-105.	2.0	14
71	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics Journal, 2019, 19, 556-563.	0.9	35
72	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. Oncologist, 2019, 24, e77-e79.	1.9	3

#	Article	IF	Citations
73	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clinical Colorectal Cancer, 2019, 18, e8-e19.	1.0	12
74	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
75	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. Drug Safety, 2019, 42, 159-179.	1.4	18
76	Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Safety, 2019, 42, 211-233.	1.4	76
77	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. Journal of Clinical Oncology, 2019, 37, 3145-3145.	0.8	3
78	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World Journal of Gastroenterology, 2019, 25, 5773-5788.	1.4	69
79	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. Journal of Clinical Oncology, 2019, 37, 594-594.	0.8	0
80	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 566-566.	0.8	0
81	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. Journal of Clinical Oncology, 2019, 37, 558-558.	0.8	4
82	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. Journal of Clinical Oncology, 2019, 37, 3545-3545.	0.8	0
83	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 3048-3048.	0.8	1
84	Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials. Cancer Research, 2019, 79, 1342-1342.	0.4	1
85	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Investigational New Drugs, 2018, 36, 709-714.	1.2	8
86	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Annals of Oncology, 2018, 29, 1528-1534.	0.6	83
87	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer, 2018, 17, e471-e488.	1.0	12
88	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	1.1	41
89	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€“Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 2018, 17, e395-e414.	1.0	25
90	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research, 2018, 24, 784-793.	3.2	23

#	Article	IF	Citations
91	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	0.8	26
92	The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. Annals of Oncology, 2018, 29, v82.	0.6	3
93	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	2.9	19
94	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
95	LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding RNA Research, 2018, 3, 195-212.	2.4	39
96	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	1.8	7
97	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	1.5	61
98	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
99	Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. BioMed Research International, 2018, 2018, 1-2.	0.9	3
100	First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. Annals of Oncology, 2018, 29, v106.	0.6	0
101	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 98.	1.1	17
102	Noninferiority of three monthsversussix months of oxaliplatinâ€based adjuvant chemotherapy for resected colon cancer. How shouldIDEAfindings affect clinical practice?. International Journal of Cancer, 2018, 143, 2342-2350.	2.3	7
103	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	1.0	18
104	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
105	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	0.8	2
106	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Journal of Clinical Oncology, 2018, 36, 3590-3590.	0.8	4
107	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the â€œBRAF, BeCoolâ€•platform.. Journal of Clinical Oncology, 2018, 36, 639-639.	0.8	2
108	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. Journal of Clinical Oncology, 2018, 36, 645-645.	0.8	1

#	Article	IF	Citations
109	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 692-692.	0.8	1
110	Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 726-726.	0.8	4
111	DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	0.8	25
112	The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, 651-651.	0.8	0
113	Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. Journal of Clinical Oncology, 2018, 36, 663-663.	0.8	0
114	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. Journal of Clinical Oncology, 2018, 36, 662-662.	0.8	3
115	Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.. Journal of Clinical Oncology, 2018, 36, 646-646.	0.8	0
116	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. Journal of Clinical Oncology, 2018, 36, 636-636.	0.8	0
117	Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 12066-12066.	0.8	0
118	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 12098-12098.	0.8	0
119	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, e15578-e15578.	0.8	0
120	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. Journal of Clinical Oncology, 2018, 36, 3575-3575.	0.8	0
121	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
122	Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. , 2018, , .		0
123	Abstract 206: The Consensus Molecular Classification (CMS) of primary colorectal tumors and their matched liver metastasis: Investigating the concordance. , 2018, , .		0
124	Abstract 2614: Macrophage erythroblast attacher (MAEA) polymorphisms are associated with clinical outcome in TRIBE study mCRC patients treated with 5-fluorouracil/bevacizumab-based therapy. , 2018, , .		0
125	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics Journal, 2017, 17, 258-264.	0.9	79
126	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics Journal, 2017, 17, 331-336.	0.9	10

#	Article	IF	Citations
127	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer, 2017, 116, 318-323.	2.9	29
128	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. Pharmacogenomics, 2017, 18, 197-200.	0.6	7
129	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Annals of Oncology, 2017, 28, 1015-1022.	0.6	24
130	Single nucleotide polymorphisms in the IGFâ€IRS pathway are associated with outcome in mCRC patients enrolled in the FIREâ€3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
131	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	1.4	85
132	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
133	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	3.2	41
134	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	1.3	54
135	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	1.3	22
136	QoL is a cool tool. Annals of Oncology, 2017, 28, 2032-2033.	0.6	2
137	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology, 2017, 71, 1008-1011.	1.6	8
138	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
139	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	1.4	21
140	New perspectives for TAS-102: TASK successful?. Lancet Oncology, The, 2017, 18, 1139-1141.	5.1	1
141	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	0.6	28
142	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
143	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer, 2017, 17, 408.	1.1	28
144	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 2017, 28, 555-561.	0.6	43

#	Article	IF	Citations
145	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics Journal, 2017, 17, 543-550.	0.9	11
146	Potential contribution of the study nurse to colorectal cancer (CRC) translational research. Annals of Oncology, 2017, 28, vi110.	0.6	1
147	Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. Journal of Clinical Oncology, 2017, 35, 615-615.	0.8	1
148	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. Anticancer Research, 2017, 37, 315-320.	0.5	21
149	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2017, 49, 834-845.	1.3	12
150	Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2017, 35, 11608-11608.	0.8	0
151	Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up.. Journal of Clinical Oncology, 2017, 35, e21654-e21654.	0.8	0
152	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. Oncology, 2016, 91, 283-288.	0.9	5
153	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. Annals of Oncology, 2016, 27, vi560.	0.6	7
154	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
155	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology, 2016, 9, 877-885.	1.3	11
156	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
157	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	1.6	25
158	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. Tumori, 2016, 102, 108-113.	0.6	4
159	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. Annals of Oncology, 2016, 27, vi152.	0.6	3
160	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Molecular Cancer Therapeutics, 2016, 15, 1740-1745.	1.9	9
161	CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine, 2016, 374, 2182-2184.	13.9	23
162	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology, 2016, 27, 843-849.	0.6	46

#	Article	IF	Citations
163	A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Targeted Oncology, 2016, 11, 293-308.	1.7	18
164	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clinical Cancer Research, 2016, 22, 3218-3226.	3.2	21
165	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	2.9	56
166	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	0.8	116
167	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. Journal of Clinical Oncology, 2016, 34, 3540-3540.	0.8	1
168	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. Journal of Clinical Oncology, 2016, 34, 3543-3543.	0.8	9
169	Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3579-3579.	0.8	3
170	Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3580-3580.	0.8	2
171	Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. Journal of Clinical Oncology, 2016, 34, 3590-3590.	0.8	1
172	Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.. Journal of Clinical Oncology, 2016, 34, e15054-e15054.	0.8	0
173	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2016, 34, TPS3629-TPS3629.	0.8	0
174	Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.. Journal of Clinical Oncology, 2016, 34, e15127-e15127.	0.8	0
175	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. Journal of Clinical Oncology, 2016, 34, TPS3627-TPS3627.	0.8	0
176	Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 11589-11589.	0.8	0
177	Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests.. Journal of Clinical Oncology, 2016, 34, 3606-3606.	0.8	0
178	NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial.. Journal of Clinical Oncology, 2016, 34, 11597-11597.	0.8	0
179	Identifying SNPs associated with progression-free survival (PFS) and overall survival (OS) in patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using Random Survival Forests (RSF).. Journal of Clinical Oncology, 2016, 34, 3604-3604.	0.8	0
180	IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.. Journal of Clinical Oncology, 2016, 34, 11600-11600.	0.8	0

#	Article	IF	Citations
181	Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors. , 2016, , .		0
182	CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine, 2016, 374, 2183.	13.9	5
183	TRIBE study: are all three cytotoxic drugs crucial? â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e578-e579.	5.1	0
184	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
185	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 290-292.	13.9	11
186	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	15.2	809
187	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	2.0	61
188	TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treatment Reviews, 2015, 41, 777-783.	3.4	115
189	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opinion on Biological Therapy, 2015, 15, 155-162.	1.4	27
190	Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics Journal, 2015, 15, 354-362.	0.9	41
191	Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics Journal, 2015, 15, 226-234.	0.9	14
192	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Annals of Oncology, 2015, 26, 724-730.	0.6	136
193	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	385
194	First-line chemotherapy for mCRCâ€"a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
195	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	0.6	137
196	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	2.9	146
197	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of Oncology, 2015, 26, 1188-1194.	0.6	153
198	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	6.1	22

#	Article	IF	Citations
199	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Annals of Oncology, 2015, 26, 2450-2456.	0.6	29
200	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	1.9	4
201	BRAF-mutated metastatic colorectal cancer between past and future. British Journal of Cancer, 2015, 113, 1634-1635.	2.9	11
202	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist, 2015, 20, 1261-1265.	1.9	42
203	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	1.1	12
204	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	2.9	226
205	Response. Journal of the National Cancer Institute, 2015, 107, djv205.	3.0	2
206	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	5.1	835
207	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of Oncology, 2015, 26, 2503.	0.6	18
208	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERÎ±-positive advanced breast cancer. Pharmacogenomics Journal, 2015, 15, 235-240.	0.9	2
209	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
210	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2015, 15, 69-76.	0.9	25
211	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. Journal of Clinical Oncology, 2015, 33, 3510-3510.	0.8	8
212	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3532-3532.	0.8	2
213	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. Journal of Clinical Oncology, 2015, 33, 3552-3552.	0.8	1
214	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 595-595.	0.8	1
215	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
216	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	0.8	46

#	Article	IF	Citations
217	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	0.8	30
218	Polymorphism of the chemokine CXCR4 to predict treatment benefit of first-line bevacizumab-based chemotherapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 635-635.	0.8	0
219	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2015, 33, 591-591.	0.8	0
220	Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. Journal of Clinical Oncology, 2015, 33, 621-621.	0.8	0
221	Effect of genetic variation on overall survival in a clinical trial of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 3562-3562.	0.8	0
222	Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.. Journal of Clinical Oncology, 2015, 33, 3554-3554.	0.8	0
223	Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC).. Journal of Clinical Oncology, 2015, 33, e14519-e14519.	0.8	0
224	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2015, 33, e22075-e22075.	0.8	0
225	Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. Journal of Clinical Oncology, 2015, 33, 3613-3613.	0.8	0
226	Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. , 2015, , .		0
227	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Research, 2015, 35, 2391-9.	0.5	1
228	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	0.8	7
229	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Pharmacogenomics Journal, 2014, 14, 135-141.	0.9	11
230	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics Journal, 2014, 14, 322-327.	0.9	11
231	Biomarkers and Response to Bevacizumabâ€"Letter. Clinical Cancer Research, 2014, 20, 1056-1057.	3.2	8
232	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
233	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 57-63.	1.3	162
234	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845

#	Article	IF	Citations
235	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics Journal, 2014, 14, 14-19.	0.9	21
236	Association of common gene variants in the WNT/Î²-catenin pathway with colon cancer recurrence. Pharmacogenomics Journal, 2014, 14, 142-150.	0.9	28
237	Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology, 2014, 32, 3519-3519.	0.8	9
238	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3524-3524.	0.8	6
239	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology, 2014, 32, 3596-3596.	0.8	4
240	mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology, 2014, 32, 3640-3640.	0.8	1
241	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664.	0.8	2
242	Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.. Journal of Clinical Oncology, 2014, 32, 521-521.	0.8	2
243	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 476-476.	0.8	0
244	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
245	CCL2 polymorphism as a predictive marker for bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, e14556-e14556.	0.8	1
246	Association of the prognostic role of CXCR4/CXCL12 polymorphism with treatment outcomes after bevacizumab-based chemotherapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e22008-e22008.	0.8	0
247	High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial;) Tj ETQq1 1 0.784314 rgBT /Overloc	0.8	
248	Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. Journal of Clinical Oncology, 2014, 32, 3571-3571.	0.8	0
249	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3537-3537.	0.8	0
250	Common genetic variants in genes involved in the Hippo pathway: Novel biomarkers in metastatic colorectal cancer patients treated with irinotecan plus cetuximab.. Journal of Clinical Oncology, 2014, 32, e14523-e14523.	0.8	0
251	Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV).. Journal of Clinical Oncology, 2014, 32, e14528-e14528.	0.8	0
252	Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 2013, 10, 472-484.	12.5	1,482

#	Article	IF	Citations
253	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. Clinical Colorectal Cancer, 2013, 12, 188-194.	1.0	28
254	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. British Journal of Cancer, 2013, 108, 2549-2556.	2.9	51
255	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. European Journal of Cancer, 2013, 49, 1501-1508.	1.3	19
256	Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono. Annals of Oncology, 2013, 24, iv22.	0.6	2
257	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq1 1 0.784314 rgBT /Overlock Nord Ovest (GONO). Annals of Oncology, 2013, 24, 2062-2067.	0.6	86
258	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	1.9	19
259	Caveolinâ€1 is a novel regulator of <scp>Kâ€RAS</scp>â€dependent migration in colon carcinogenesis. International Journal of Cancer, 2013, 133, 43-57.	2.3	45
260	Reply: Comment on â€˜Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumabâ€™. British Journal of Cancer, 2013, 109, 3129-3130.	2.9	3
261	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. Annals of Oncology, 2013, 24, iv21.	0.6	5
262	Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology, 2013, 24, iv15.	0.6	1
263	Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. Annals of Oncology, 2013, 24, iv28.	0.6	0
264	Conference Scene: Annual Meeting of the American Society of Clinical Oncology. Colorectal Cancer, 2013, 2, 401-404.	0.8	0
265	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Colorectal Cancer, 2013, 2, 411-417.	0.8	1
266	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	1.1	64
267	FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.. Journal of Clinical Oncology, 2013, 31, 3505-3505.	0.8	46
268	Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum).. Journal of Clinical Oncology, 2013, 31, 3527-3527.	0.8	8
269	Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 3613-3613.	0.8	4
270	Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.. Journal of Clinical Oncology, 2013, 31, e14577-e14577.	0.8	2

#	Article	IF	Citations
271	FOLFOXIRIÂplus bevacizumab (bev) versus FOLFIRIÂplus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	25
272	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.. Journal of Clinical Oncology, 2013, 31, 382-382.	0.8	1
273	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 393-393.	0.8	1
274	Correlation of messenger RNA expression patterns of ERCC1, TS, EGFR, and VEGFR2 with KRAS and BRAF mutational status in advanced colorectal cancer: Implications for targeted therapies.. Journal of Clinical Oncology, 2013, 31, 383-383.	0.8	2
275	â€œHER Majesty's a Pretty Nice Girl but She Changes From Day to Dayâ€•. Journal of Clinical Oncology, 2012, 30, 465-466.	0.8	1
276	High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. Oncologist, 2012, 17, 823-829.	1.9	74
277	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Annals of Oncology, 2012, 23, 135-141.	0.6	79
278	Influence of Sex on the Survival of Patients With Esophageal Cancer. Journal of Clinical Oncology, 2012, 30, 2265-2272.	0.8	112
279	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecanâ€“cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	0.6	34
280	Selecting the best targeted agent in firstâ€line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 528-535.	1.4	2
281	The possible role of chemotherapy in antiangiogenic drug resistance. Medical Hypotheses, 2012, 78, 646-648.	0.8	17
282	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
283	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Annals of Oncology, 2012, 23, 1370-1371.	0.6	7
284	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40
285	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
286	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	1.0	1
287	PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients. Annals of Oncology, 2012, 23, iv22.	0.6	0
288	P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV). Annals of Oncology, 2012, 23, iv105-iv106.	0.6	0

#	Article	IF	Citations
289	Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence. Clinical Cancer Research, 2012, 18, 645-653.	3.2	173
290	Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1187-1196.	1.2	27
291	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis, 2012, 15, 275-286.	3.7	61
292	Clinical impact of antiâ€epidermal growth factor receptor monoclonal antibodies in firstâ€line treatment of metastatic colorectal cancer. Cancer, 2012, 118, 1523-1532.	2.0	34
293	PML as a potential predictive factor of oxaliplatin/fluoropyrimidineâ€based first line chemotherapy efficacy in colorectal cancer patients. Journal of Cellular Physiology, 2012, 227, 927-933.	2.0	5
294	Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).. Journal of Clinical Oncology, 2012, 30, 3518-3518.	0.8	1
295	Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 3540-3540.	0.8	6
296	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	0.8	6
297	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3
298	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69
299	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
300	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. British Journal of Cancer, 2011, 104, 1262-1269.	2.9	85
301	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology, 2011, 78, 243-251.	2.0	31
302	Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics, 2011, 12, 1077-1080.	0.6	11
303	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. Journal of the National Cancer Institute, 2011, 103, 21-30.	3.0	160
304	Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Annals of Oncology, 2011, 22, 1141-1146.	0.6	54
305	Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?. Journal of Clinical Oncology, 2011, 29, e206-e207.	0.8	17
306	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. Current Cancer Drug Targets, 2010, 10, 37-45.	0.8	12

#	Article	IF	Citations
307	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2010, 66, 559-566.	1.1	5
308	Insulinâ€like growth factor 1 expression correlates with clinical outcome in Kâ€RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	2.3	67
309	Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1076-1077.	2.9	1
310	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics, 2010, 11, 1247-1256.	0.6	6
311	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Annals of Oncology, 2010, 21, 1565.	0.6	38
312	Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. Annals of Oncology, 2010, 21, 181.	0.6	5
313	Palliative treatment of unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 63-77.	0.9	18
314	Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting â€œLost in TranslationALâ€?. Journal of Clinical Oncology, 2010, 28, e173-e174.	0.8	4
315	Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. Oncology, 2010, 79, 187-196.	0.9	77
316	How useful is adjuvant irinotecan in stage IV CRC?. Nature Reviews Clinical Oncology, 2010, 7, 190-191.	12.5	3
317	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	5.1	234
318	Genetic modulation of the Let-7 microRNA binding to KRAS 3â€²-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximabâ€“irinotecan. Pharmacogenomics Journal, 2010, 10, 458-464.	0.9	109
319	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental and Clinical Cancer Research, 2010, 29, 58.	3.5	46
320	Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Annals of Oncology, 2010, 21, 2382-2389.	0.6	94
321	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 167-181.	1.4	7
322	Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics Journal, 2009, 9, 78-84.	0.9	23
323	Do we need biopsies of metastases for colorectal cancer patients?. British Journal of Cancer, 2009, 101, 374-375.	2.9	2
324	Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer, 2009, 100, 881-887.	2.9	164

#	Article	IF	Citations
325	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer, 2009, 100, 1720-1724.	2.9	30
326	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 945-949.	1.4	15
327	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. Annals of Surgery, 2009, 249, 420-425.	2.1	213
328	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer, 2009, 9, 303.	1.1	66
329	VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. International Journal of Colorectal Disease, 2009, 24, 165-170.	1.0	47
330	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 965-969.	1.1	15
331	Pharmacokinetics, a main actor in a manyâ€sided approach to severe 5â€FU toxicity prediction. British Journal of Clinical Pharmacology, 2009, 67, 132-134.	1.1	9
332	Refractory neuroendocrine tumorâ€"response to liposomal doxorubicin and capecitabine. Nature Reviews Clinical Oncology, 2009, 6, 670-674.	12.5	5
333	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	2.9	509
334	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
335	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does â€œAdjuvantâ€•Chemotherapy Play a Role After Resection?. Annals of Surgery, 2009, 250, 655.	2.1	0
336	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0
337	Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. British Journal of Cancer, 2008, 99, 716-721.	2.9	29
338	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 7-14.	1.0	15
339	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics Journal, 2008, 8, 278-288.	0.9	97
340	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. European Journal of Cancer, Supplement, 2008, 6, 86-90.	2.2	2
341	Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1427-1434.	0.8	124
342	Optimal approach to potentially resectable liver metastases from colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1533-1539.	1.1	4

#	Article	IF	Citations
343	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 98, 1312-1319.	2.9	63
344	High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. Oncologist, 2008, 13, 1270-1275.	1.9	218
345	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics, 2008, 9, 55-69.	0.6	12
346	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Current Opinion in Oncology, 2008, 20, 459-465.	1.1	11
347	Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. Journal of Clinical Oncology, 2007, 25, 3930-3935.	0.8	121
348	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. Journal of Clinical Oncology, 2007, 25, 1816-1818.	0.8	56
349	Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. Journal of Clinical Oncology, 2007, 25, 1247-1254.	0.8	250
350	Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2006, 13, 58-65.	0.7	156
351	First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology, 2006, 17, 1249-1254.	0.6	22
352	Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy?. Journal of Clinical Oncology, 2006, 24, 4668-4669.	0.8	0